Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Ferris ME, Harward DH, Bickford K, Layton JB, Ferris MT, Hogan SL, Gipson DS, McCoy LP, Hooper SR. A clinical tool to measure the components of health-care transition from pediatric care to adult care: the UNC TR(x)ANSITION scale. Ren Fail. 2012;34(6):744-53. doi: 10.3109/0886022X.2012.678171
So TY, Layton JB, Bozik K, Farrington E, Gipson PE, Gibson K, Primack W, Conley, 3rd W, Gipson DS, Ferris M. Cognitive pharmacy services at a pediatric nephrology and hypertension clinic. Ren Fail. 2011 Jan 10;33(1):19-25. doi: 10.3109/0886022X.2010.536291
Phanikumar CV, Maitra B. Valuing urban bus attributes: an experience in Kolkata. J Public Transport. 2006;9(2):69-87. doi: 10.5038/2375-0901.9.2.4
Phani Kumar CV, Basu D, Maitra B. Modeling generalized cost of travel for rural bus users: a case study. J Public Transport. 2004;7(2):59-72. doi: 10.5038/2375-0901.7.2.4